Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.

Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.

Researchers say the popularity of convalescent plasma makes it more difficult to gather high-quality data on its efficacy.

Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.

The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.

The treatment, Trikafta, increases lung function in most patients with the disease—but comes with a hefty price tag.

The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.

The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.

Two coauthors of a new study discuss their findings about nearly 170 facilities in the southwestern US selling unproven therapies—and what should be done about them.